Molecular Imaging Market
FluoroPharma’s products utilize positron emission tomography (PET) technology, a molecular imaging platform that is growing rapidly due to its inherently superior sensitivity and specificity compared to other imaging options. Molecular imaging fulfills unmet needs in diagnosis and follow-up therapy by enabling visualization, characterization and measurement of biological processes at the molecular and cellular level. Unlike more commonly known imaging modalities – MRI, CT, and Ultrasound– that provide insight into the anatomical manifestation of disease, molecular imaging techniques, such as PET, provide insight into physiology and can detect disease before anatomical manifestation is identified. The market for molecular imaging agents currently exceeds $1.7 billion annually.
In the US today, symptomatic coronary artery disease (CAD) affects more than 13 million patients and accounts for more than 30% of all deaths. Cardiologists’ demand for faster, more accurate diagnostic tools continuously drives the development of non-invasive techniques with increased sensitivity and accuracy for the detection and assessment of acute and chronic CAD. Molecular imaging is currently used in more than 9 million myocardial perfusion imaging (MPI) procedures, the standard test for diagnosing CAD.
Additional Diagnostic Markets
Alzheimer’s Disease - As many as 5.2 million people in the United States are living with Alzheimer’s and 10 million baby boomers will develop Alzheimer's in their lifetime. Currently, there is no single diagnostic test that proves a person has AD. FluoroPharma is developing new options for early detection and treatment of Alzheimer’s, to improve patient care and create new paths for AD management.
Prostate cancer - Prostate cancer is the most frequently diagnosed and second most lethal malignancy among men in the United States. FluoroPharma is developing new compounds to enable earlier and more accurate diagnosis of prostate cancer.